


With respect to the requirement to elect a disclosed indoline derivative represented by formula (I), Applicants elect the compound of claim 2, (-)-1-(3-hydroxypropyl)-5-((2R)-2-({2-[(2-{(2,2,2-trifluoroethyl)oxylphenyl}oxy)ethyl]amino}propyl)-2,3-dihydro-1H-indol-7-carboxamide (see the structural formula below), as a single indoline derivative represented by formula (I):



With respect to electing at least one neurogenic disorder, Applicants assume that the Examiner means to elect one neurogenic disorder, and if that is the case, Applicants elect spinal cord involvement.

With respect to claims that read on the elected species, claims 1-3 and 6 read on the elected species.


With respect electing whether or not the method further comprises the administration, in combination, with one or more other agents used for overactive bladder accompanied with neurogenic disorder, Applicants elect the method **not further comprising** administration in combination with other agents.

RESPONSE TO ELECTION/RESTRICTIONS
U.S. Application No.: 10/598,533

Attorney Docket No.: Q96716

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Peter D. Olexy", is written over a horizontal line.

Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 12, 2010